Cryoport, Inc. (NASDAQ:CYRX) CEO Jerrell Shelton Sells 2,980 Shares

Cryoport, Inc. (NASDAQ:CYRX) CEO Jerrell Shelton sold 2,980 shares of the business’s stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $6.94, for a total value of $20,681.20. Following the completion of the transaction, the chief executive officer now owns 762,419 shares of the company’s stock, valued at $5,291,187.86. This represents a 0.39 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

Jerrell Shelton also recently made the following trade(s):

• On Monday, March 17th, Jerrell Shelton sold 4,620 shares of Cryoport stock. The shares were sold at an average price of $6.29, for a total transaction of $29,059.80.
• On Monday, March 10th, Jerrell Shelton sold 4,173 shares of Cryoport stock. The stock was sold at an average price of $4.88, for a total transaction of $20,364.24.

Cryoport Stock Down 0.3 %

Cryoport stock opened at $6.22 on Thursday. Cryoport, Inc. has a fifty-two week low of $4.58 and a fifty-two week high of $20.11. The firm has a market capitalization of $310.44 million, a PE ratio of -1.84 and a beta of 1.67. The company’s 50-day moving average is $6.73 and its 200-day moving average is $7.34. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.70 and a quick ratio of 5.32.

Cryoport (NASDAQ:CYRX) last posted its quarterly earnings results on Tuesday, March 4th. The company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.09). Cryoport had a negative net margin of 70.08% and a negative return on equity of 13.35%. The business had revenue of $59.53 million during the quarter, compared to the consensus estimate of $58.71 million. During the same quarter last year, the company posted ($0.29) EPS. Sell-side analysts anticipate that Cryoport, Inc. will post -0.99 earnings per share for the current year.

Institutional Investors Weigh In On Cryoport

Several hedge funds have recently bought and sold shares of the stock. Point72 Asia Singapore Pte. Ltd. lifted its holdings in Cryoport by 148.7% during the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company’s stock worth $28,000 after purchasing an additional 2,120 shares during the last quarter. Lazard Asset Management LLC bought a new position in Cryoport during the 4th quarter worth $51,000. Avanza Fonder AB acquired a new stake in shares of Cryoport during the fourth quarter worth $64,000. Quarry LP bought a new stake in shares of Cryoport in the fourth quarter valued at about $69,000. Finally, Dynamic Technology Lab Private Ltd acquired a new position in shares of Cryoport in the third quarter valued at about $82,000. 92.90% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on CYRX shares. UBS Group raised shares of Cryoport from a “neutral” rating to a “buy” rating and set a $10.00 target price for the company in a research note on Monday. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price target on shares of Cryoport in a research note on Wednesday, March 5th. Finally, Guggenheim assumed coverage on shares of Cryoport in a report on Thursday, December 19th. They issued a “buy” rating and a $11.00 price objective on the stock. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $11.67.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.